

Synthesis, Spectral Characterization and Screening of New Triazolo Thienopyrimidine Derivatives for their Antimicrobial Activity

Srujana Muthadi¹, Shirisha Thadishetti², Jyothi Bandi², Mamatha Kasula^{3*}

¹Department of Pharmacy, Chaitanya College of Pharmacy Education and Research, Warangal, A.P, India.

²Medicinal Chemistry Research Division, Vaagdevi College of Pharmacy, Hanamkonda, Warangal, A.P, India.

³Department of Chemistry, Kakatiya University, Warangal-506009, Andhra Pradesh, India.

Received on: 22-04-2014; Revised and Accepted on: 30-04-2014

ABSTRACT

In this study a series of novel 2-Methyl-3-(1-methyl-1H-[1,2,3] triazol-4-yl-methyl)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-4-one derivatives (IVa-e) were synthesized by treating 2-Methyl-3-prop-2-ynyl-5,6,7,8-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyrimidine-4-one (III) and its derivatives with alkyl azides in the presence of copper sulphate and dimethylsulphoxide. By treating 2-Methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-d]pyrimidine-4-one(II) and its derivatives with propargyl bromide in the presence of potassium carbonate in acetone results in the formation of N-substituted compound-III and its derivatives. The compound-II and its derivatives were synthesized by treating 2-amino-thiophene -3-carboxylic acid ethyl ester (I) with alkyl/aryl nitrile in the presence of dry HCl and 1,4-dioxane. The newly synthesized compounds (IVa-h) were purified, separated, and characterized by TLC, IR, ¹H NMR and Mass spectra. These representative analogues were screened for invitro antimicrobial activity. The compounds exhibited significant antibacterial and antifungal activities.

Key words : Thieno pyrimidines, dimethylsulphoxide, Antimicrobial IC50 values.

INTRODUCTION

Pyrimidine derivatives are very important heterocyclic compounds especially in life sciences, medicinal chemistry and in pesticidal chemistry and continue to attract great interest due to a wide variety of interesting biological activities such as anti-inflammatory, anticancer, antiviral, and antimicrobial activities. Fused pyrimidinones were reported to exhibit wide spectrum of activities like bronchodilatory [1], antihistaminic [2], anticancer [3] among the pyrimidinones, thienopyrimidines have been evaluated pharmacologically and used as antimicrobial [4], analgesic [5], anti-inflammatory [5] and antiviral [6] agents.

1,2,4-triazoles possess important pharmacological activities like anti-inflammatory [7], antifungal [8] and cytotoxic [9] activities. Fused triazoles are proved to have diverse applications as antibacterial [10] and anticancer [11] agents. Recent literature reveals that when one heterocyclic system is coupled with another, a molecule with enhanced biological activity is produced (Click Chemistry).

Click chemistry is a modular approach that uses only the most practical and reliable chemical transformations. Which describes the chemistry tailored to generate substances quickly and reliably by joining small units together¹². Its applications are increasingly found in all aspects of drug discovery, ranging from lead finding through combinatorial chemistry and target template *in situ* chemistry, to proteomics and DNA research, using bio-conjugation reactions.

Considering all these potential biological activities of thienopyrimidines and triazoles which were reported to be more potent and less toxic, it has been felt worthwhile to take up the

present investigation in an effort to incorporate triazole ring system into thienopyrimidine derivatives with methylene bridge to synthesize novel N-alkynyl triazolo thienopyrimidines as antimicrobial agents.

MATERIALS AND METHODS

All the chemicals used were Aldrich, Fluka and Merck company. Thin layer chromatography (TLC) was performed on E.Merk AL silica gel 60 F254 plates and visualized under UV light. The IR spectra were determined in a Perkin-Elmer transform (FTIR spectrum). ¹H NMR spectra were recorded on varian EM-360(400MHz mercury plus) spectrometer in DMSO or CDCl₃ and calibrated using solvent signals. All chemical shifts recorded in δ (ppm) using TMS as an internal standard. The mass spectra were recorded on Agilent ion trap MS at energy of ionizing electron equal to 70ev.

2-Methyl-5,6,7,8-tetrahydrobenzo[b]thieno[2,3-d]pyrimidine-4-one(II) was prepared from 2-amino-thiophene -3-carboxylic acid ethyl ester (I) with alkyl/aryl nitrile in the presence of dry HCl and 1,4-dioxane. The synthesized compound-II was treated with propargyl bromide in the presence of potassium carbonate in acetone results in the formation of N-substituted compound-III and its derivatives. The synthesized compound-III and its derivatives were treated with alkyl azides in the presence of copper sulphate and dimethylsulphoxide yields 2-Methyl-3-(1-methyl-1H-[1,2,3]triazol-4-yl-methyl)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-one (IV) and its derivatives. The newly synthesized triazolo thienopyrimidine derivatives were characterized by both physical and spectral data. These compounds were evaluated for their antimicrobial activity. The melting points of synthesized compounds were determined with an electro thermal melting point apparatus.

*Corresponding author:

Mamatha Kasula



Department of Chemistry,

Kakatiya University, Warangal-506009, Andhra Pradesh, India.

Mobile No:8499835700

*E-Mail: mamatakasula@gmail.com

Scheme:

**Synthesis of Triazolo Thienopyrimidines:****Synthesis of Ethyl 2-Amino- 4,5- Substituted Thiophene- 3- Carboxylate (I):**

An equimolar quantities of (0.01 moles) of sulphur, ethyl cyano acetate and respective ketone were taken in 15 ml of ethanol

in conical flask. The mixture was stirred for 5 min and morpholine was added slowly at 50°C and stirred continuously for 5 hours at room temperature and the complete mixture solution was kept in refrigerator overnight. The crystals obtained were collected by filtration and recrystallized with ethanol.

Table No. 1:

S. No.	Compound	R ₁	R ₂	Molecular formula	Melting point (°C)	% yield
1	Ia	-(CH ₂) ₄ -		C ₁₁ H ₁₅ NO ₂ S	110-115	85
2	Ib	CH ₃	CH ₃	C ₉ H ₁₃ NO ₂ S	100-105	65
3	Ic	-(CH ₂) ₃ -		C ₁₀ H ₁₃ NO ₂ S	95-98	50

Step-1: Synthesis of 2,5,6-Substituted Thienopyrimidin-4-One (II):

2-Amino thiophen-4,5-disubstituted-3-carboxylic acid ethyl ester (0.001 moles) was treated with alkyl or aryl nitrile (0.002 moles) in dry dioxane. Dry HCl gas was passed using dip rod till the starting material was disappeared in TLC. Excess nitrile present in

the reaction mixture was removed under pressure and the solution was poured in crushed ice and the mixture was neutralized with sodium bicarbonate solution. The precipitate was collected by vacuum filtration.

Table No. 2:

S. No.	Compound	R ₁	R ₂	R	Molecular formula	Melting point (°C)	% yield
1	IIa	-(CH ₂) ₄ -	CH ₃		C ₁₁ H ₁₂ N ₂ OS	250-256	80
2	IIb	-(CH ₂) ₄ -	C ₆ H ₅		C ₁₆ H ₁₄ N ₂ OS	275-280	70
3	IIc	CH ₃	CH ₃	CH ₃	C ₉ H ₁₀ N ₂ OS	270-275	80
4	IId	-(CH ₂) ₃ -	CH ₃		C ₁₀ H ₁₀ N ₂ OS	280-285	75

Step-2: Synthesis of Propargylated Thienopyrimidines (III):

Compound-II (3 mmoles) and potassium carbonate (6 mmoles) in 1:2 ratio were taken in 20 ml of acetone in two necked flask. To this mixture propargyl bromide was added dropwise under

heating and refluxed for 5 hours, and the mixture was concentrated in vacuo and added to the ice cold water. The obtained N-propargylated product was collected by filtration and separated by column chromatography.

Table No. 3:

S. No.	Compound	R	R ₁	R ₂	Molecular formula	Melting point (°C)	% yield
1	IIIa	CH ₃	-(CH ₂) ₄ -		C ₁₄ H ₁₄ N ₂ OS	175-180	10.41
2	IIIb	C ₆ H ₅	-(CH ₂) ₄ -		C ₁₉ H ₁₆ N ₂ OS	175-180	20.83
3	IIIc	CH ₃	CH ₃	CH ₃	C ₁₂ H ₁₂ N ₂ OS	165-170	28.73
4	IIId	CH ₃	-(CH ₂) ₃ -		C ₁₃ H ₁₂ N ₂ OS	180-185	21.06

Step-3: Synthesis of 1,4-Substituted 1,2,3- Triazolyl Thienopyrimidines (IV):

Equimolar proportions of N-substituted alkynyl thienopyrimidine and copper iodide were taken in DMSO in round bottomed flask and cooled to 0°C. To this an alkyl azide was added

dropwise under stirring, and the stirring was continued for 12 hours. The concentrated reaction mixture was poured in to the crushed ice. The crude triazolyl thienopyrimidine product was collected by extraction with ethyl acetate. The product was purified by column chromatography.

Table No. 4 :

S. No.	Compound	R	R ₁	R ₂	R ₃	Molecular formula	Mol.wt	Melting point (°C)	% yield
1	IVa	CH ₃	-(CH ₂) ₄ -	CH ₃		C ₁₅ H ₁₇ N ₅ OS	315	198-205	86.06
2	IVb	CH ₃	-(CH ₂) ₄ -	C ₂ H ₅		C ₁₆ H ₁₉ N ₅ OS	329	222-227	70.58
3	IVc	CH ₃	-(CH ₂) ₄ -	C ₃ H ₇		C ₁₇ H ₂₁ N ₅ OS	343	200-205	69.81

4	IVd	CH ₃	CH ₃	CH ₃	CH ₃	C ₁₃ H ₁₅ N ₅ OS	289	200-208	67.46
5	IVe	CH ₃	CH ₃	CH ₃	C ₂ H ₅	C ₁₄ H ₁₇ N ₅ OS	303	190-196	58.12
6	IVf	CH ₃	CH ₃	CH ₃	C ₃ H ₇	C ₁₅ H ₁₉ N ₅ OS	317	195-200	54.94
7	IVg	CH ₃	-(CH ₂) ₃ -		CH ₃	C ₁₄ H ₁₅ N ₅ OS	301	225-228	60.70
8	IVh	CH ₃	-(CH ₂) ₃ -		C ₂ H ₅	C ₁₅ H ₁₇ N ₅ OS	315	220-225	57.92

Compound(IVa):**2-Methyl-3-(1-methyl-1H-[1,2,3]triazol-4-ylmethyl)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.8(s, 3H, CH₃), 1.3(s, 4H, 2CH₂), 2.4- 2.9(m, 4H, 2CH₂), 3.7(s, 3H, N-CH₃), 4.3(s, 2H, N-CH₂) and 7.3(s, 1H, C-H), **ESI-MS** m/z: 315(M+H)⁺m/z calculated for C₁₅H₁₇N₅OS [M+H]⁺ 314 found 314.18.

Compound(IVb):**2-Methyl-3-(1-ethyl-1H-[1,2,3]triazol-4-ylmethyl)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.8(s, 3H, CH₃), 1.3(s, 3H, CH₃), 1.7- 2.0(d, 4H, 2CH₂), 2.5-2.8(d, 4H, 2CH₂) 3.9(s, 2H, N-CH₂), 4.3(s, 2H, N-CH₂) and 7.3(s, 1H, C-H), **ESI-MS** m/z: 329(M+H)⁺m/z calculated for C₁₆H₁₉N₅OS [M+H]⁺ 328 found 328.28.

Compound(IVc):**2-Methyl-3-(1-Propyl-1H-[1,2,3]triazol-4-ylmethyl)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.8(s, 3H, CH₃), 1.3(s, 3H, CH₃), 1.7- 2.0(d, 4H, 2CH₂), 2.1-2.3(d, 4H, 2CH₂) 2.5-2.8(d, 4H, 2CH₂) 3.9(s, 2H, N-CH₂), 4.3(s, 2H, N-CH₂) and 7.3(s, 1H, C-H), **ESI-MS** m/z: 343(M+H)⁺m/z calculated for C₁₇H₂₁N₅OS [M+H]⁺ 342 found 342.73.

Compound(IVd):**2,5,6-Trimethyl-3-(1-methyl-1H-[1,2,3]triazol-4-ylmethyl)-3H-thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.9(s, 3H, CH₃), 1.4(d, 3H, CH₃), 2.3- 2.7(m, 4H, 2CH₂), 3.7(s, 3H, N-CH₂), 4.3(s, 2H, N-CH₂) and 7.1(s, 1H, C-H), **ESI-MS** m/z: 289(M+H)⁺m/z calculated for C₁₃H₁₅N₅OS [M+H]⁺ 288 found 288.15.

Compound(IVe):**2,5,6-Trimethyl-3-(1-ethyl-1H-[1,2,3]triazol-4-ylmethyl)-3H-thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.9(s, 3H, CH₃), 1.4(d, 3H, CH₃), 2.3- 2.7(m, 4H, 2CH₂), 3.7(s, 2H, N-CH₂), 4.2(s, 2H, N-CH₂) and 7.3(s, 1H, C-H), **ESI-MS** m/z: 303(M+H)⁺m/z calculated for C₁₄H₁₇N₅OS [M+H]⁺ 302 found 302.80.

Compound(IVf):**2,5,6-Trimethyl-3-(1-propyl-1H-[1,2,3]triazol-4-ylmethyl)-3H-thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.9(s, 3H, CH₃), 1.4(d, 3H, CH₃), 2.5- 2.9(m, 6H, 3CH₂), 3.7(s,

2H, N-CH₂), 4.2(s, 2H, N-CH₂) and 7.3(s, 1H, C-H), **ESI-MS** m/z: 317(M+H)⁺m/z calculated for C₁₅H₁₉N₅OS [M+H]⁺ 316 found 316.9.

Compound(IVg):**2-methyl-3-(1-methyl-1H-[1,2,3]triazol-4-ylmethyl)-1,2,3,5-tetrahydro-cyclopenta[4,5]thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.9(s, 3H, CH₃), 1.3(s, 2H, CH₂), 2.5(s, 3H, CH₃), 2.8(s, 3H, CH₂) 2.9-3.2(d, 2H, CH₂), 3.5(s, 3H, N-CH₃), and 7.3(s, 1H, C-H), **ESI-MS** m/z: 301(M+H)⁺m/z calculated for C₁₄H₁₅N₅OS [M+H]⁺ 300 found 300.64.

Compound(IVh):**2-methyl-3-(1-ethyl-1H-[1,2,3]triazol-4-ylmethyl)-1,2,3,5-tetrahydro-cyclopenta[4,5]thieno[2,3-d]pyrimidine-4-one:**

FT-IR in cm⁻¹(KBr) 3445(v N-H), 3073(C-H stretch in alkenes), 2926(C-H stretch in methylene), 2855(C-H stretch in methyl), 1672(v C=O), 1551(C=N), 790.34(v C-S), ¹H NMR (CDCl₃, δppm): 0.9(s, 3H, CH₃), 1.3(s, 2H, CH₂), 2.5(s, 3H, CH₃), 2.8(s, 3H, CH₂) 2.9-3.2(d, 2H, CH₂), 3.7(s, 2H, N-CH₂), 6.2(s, 2H, N-CH₂) and 7.3(s, 1H, C-H), **ESI-MS** m/z: 315(M+H)⁺m/z calculated for C₁₅H₁₇N₅OS [M+H]⁺ 314 found 314.98.

Antimicrobial Activity:

All the newly synthesized compounds were screened for their antibacterial and antifungal activities. For antibacterial study microorganisms employed were E.coli, K.pneumonia (gram -ve bacteria), S.aureus, B.subtilis (gram +ve bacteria). For antifungal study microorganism employed was Candida albicans. Both antibacterial and antifungal activities were investigated by using filter paper strip method in nutrient agar medium, and Sabouraud dextrose of czapexs dox agar medium by using drug standards Streptomycin and Fluconazole. The compounds were tested invitro for their antibacterial activity which are pathogenic to human beings. The Inoculation period for the test organisms in nutrient agar media was found to be 37± 1°C for 24hrs, whereas for antifungal activity the zone of inhibition in mm was measured after 24 hrs of inhibition at 25°C.


RESULTS AND DISCUSSIONS

Formation of 1,4-substituted-1,2,3-triazolyl thieno pyrimidines (**IV a-h**) were confirmed by recording their IR, ¹HNMR and Mass spectral analysis. **IR** spectrum of compound IVa showed absorption bands at 3445, 3073, 2926, 2855, 1672, 1551, and 790.34 cm⁻¹ due to v N-H, C-H str in alkene, C-H stretching in methylene group, C-H str in methyl, C=O, C=N and C-S respectively. Similarly the mass spectrum was recorded and reported as (M+1) values. For the compound IVa. a molecular weight 315 is consistence with the molecular formula C₁₅H₁₇N₅OS. The values for the remaining compounds have been presented under the experimental part.

From the antimicrobial study the results conclude that among the newly synthesized triazolyl thienopyrimidines, IVa, IVc, and IVe exhibited good antibacterial activity against K.pneumoniae, E.coli, S.aureus, B.subtilis, and the compound IVa and IVh exhibited better antifungal activity against Candida albicans.

Table No. 5:

S.NO	R	R ₁	R ₂	R ₃	Antibacterial potency(IC ₅₀)				Antifungal(IC ₅₀)
					E.c	K.p	S.a	B.s	C.a
Via	CH ₃	-(CH ₂) ₄ -		CH ₃	384.6	360.0	330.2	374.8	285
Vib	CH ₃	-(CH ₂) ₄ -		C ₂ H ₅	454.6	505.7	399.4	384.6	750
Vic	CH ₃	-(CH ₂) ₄ -		C ₃ H ₇	518.3	296.1	415.9	527.0	435
VId	CH ₃	CH ₃	CH ₃	CH ₃	312.3	366.2	412.5	355	355
VIe	CH ₃	CH ₃	CH ₃	C ₂ H ₅	306.5	296.1	410.2	360	360
VIf	CH ₃	CH ₃	CH ₃	C ₃ H ₇	306.5	390.1	434.0	520	520
VIg	CH ₃	-(CH ₂) ₃ -		CH ₃	485.4	501.6	415.3	535.9	435
VIh	CH ₃	-(CH ₂) ₃ -		C ₂ H ₅	553.1	455.0	335.1	447.2	280

Fig. 1: ¹H NMR

CONCLUSION

In conclusion the Synthesis, Characterization, Pharmacological analysis of 2-Methyl-3-(1-methyl-1H-[1,2,3]triazol-4-ylmethyl)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-one and its analogues was done. The representative examples were Screened in vitro antibacterial activity and antifungal activity. The biological evaluation indicate that the molecules IVa, IVc, and IVe exhibited better antibacterial activity where as IVa and IVh showed better antifungal activity. The results were in agreement with the experimental observations.

REFERENCE:

1. Abdallah M.A., Naturforsch Z. **2002**; 57b: 699-706.
2. Abdel-Rahman B.A., El-Gazzar., Hoda A.R., Hussein., Hend N., Hafez. *Acta Pharm.*, **2007**; 57: 395-411.
3. Alagar Swamy V., Pathak U S., Raja Solomon V., Meena S., Rama Seshu K.V., Rajesh R. *Ind. J. of Heterocycl. Chem.*, **2004**; 13: 347.
4. Kolb H.C, Finn.M.G, Sharpless K.B. Click Chemistry, *Angew. Chem. Int. Ed.*, **2001**; 40: 2004-2021.
5. Kolb H.C and Sharpless K.B. *Drug Discovery Today*, **2003**; 8: **1128-1137**.
6. Matsumoto M., Ishida K., Konnagai A., Maebashi K., Asaoka T. *Antimicrobial Agents and Chemotherapy*, **2002**; 46: 308-314.
7. Padmavathi V., Sudhakar Reddy G., Padmaja A., Kondaiah P., Ali-Shazia. *European J. of Medicinal Chemistry*, **2008**; 1-7.
8. Rao A.R., Bahekar R.H. *Arzeim Forsch/Drug Res.*, **2000**; 50: 712.
9. Rao A.R., Reddy V.M., Ayzeim *Forsch/Drug Res*, **1993**; 43: 663/*Pharmazie*, **1992**; 47: 794.
10. *Microbiological Assays*, B.P., **1953**; 11: 796.
11. *Microbiological Assays and Tests*, I.P., **1996**; 2: 100.
12. Shehata E.A., Abdelal A.M., Sherbeny MA.El. *Medicinal Chemistry Research*, **1996**; 148: 163.

Conflict of interest: The authors have declared that no conflict of interest exists.

Source of support: Nil




Fig. 2: FT-IR